Skip to content
2000
Volume 20, Issue 3
  • ISSN: 1574-8863
  • E-ISSN: 2212-3911

Abstract

Infliximab (INF), a murine human monoclonal antibody, is a substantially more successful biologic than topical drugs for treating mild to severe psoriasis because it clears the skin rapidly due to its fast onset of action. Loss of responsiveness over time and some adverse effects, especially the experience of infusion reactions, are the major causes of non-compliance with INF medication. Therefore, evaluation of the long-term reliability of anti-tumor necrosis factor (TNF) medications is necessary for the assessment of the risks associated with long-term anti-TNF therapy. For psoriasis, there are registered safety statistics; however, these individuals might not receive the same level of care as those in a randomized study. Few assessments of the safety of anti-TNF medications across indications, including their biosimilars, are present, but it’s still unknown how anti-infliximab antibodies arise and produce harmful effects. INF biosimilars, when subjected to human studies to reduce cost and improve access, provide therapeutic benefits with associated adverse events, showing variations in incidence depending upon varying patient populations and no new safety indications. During therapy, certain individuals develop antibodies against INF, which are believed to be linked to a loss of response (LOR). Additional research aimed at identifying individuals who are susceptible to treatment resistance is likely to assist doctors in accurately selecting the appropriate candidates for anti-TNF-α therapy and enhancing the long-term effectiveness of the treatment. From clinical studies, we expect to learn about how to utilize INF or its biosimilars more effectively in the management of psoriasis. Therefore, the paper focuses on the efficacy and safety monitoring of INF and developed biological therapies.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cds/10.2174/0115748863320685240830092746
2024-09-18
2025-10-03

  • From This Site

    /content/journals/cds/10.2174/0115748863320685240830092746
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. KamiyaK. KishimotoM. SugaiJ. KomineM. OhtsukiM. Risk factors for the development of psoriasis.Int. J. Mol. Sci.20192018434710.3390/ijms20184347 31491865
     [Google Scholar]
  2. KubotaK. KamijimaY. SatoT. Epidemiology of psoriasis and palmoplantar pustulosis: A nationwide study using the Japanese national claims database.BMJ Open201551e00645010.1136/bmjopen‑2014‑006450 25588781
     [Google Scholar]
  3. NaC.H. ChungJ. SimpsonE.L. Quality of life and disease impact of atopic dermatitis and psoriasis on children and their families.Children 201961213310.3390/children6120133 31810362
     [Google Scholar]
  4. AdesanyaE.I. MatthewmanJ. SchonmannY. Factors associated with depression, anxiety and severe mental illness among adults with atopic eczema or psoriasis: A systematic review and meta-analysis.Br. J. Dermatol.2023188446047010.1093/bjd/ljac132 36745557
     [Google Scholar]
  5. ArmstrongA.W. MehtaM.D. SchuppC.W. GondoG.C. BellS.J. GriffithsC.E.M. Psoriasis prevalence in adults in the United States.JAMA Dermatol.2021157894094610.1001/jamadermatol.2021.2007 34190957
     [Google Scholar]
  6. SylviningrumT. PutrantiI.O. SariO.P. ArjadiF. SudibyoE.S. ManikS.N. Association between HLA-Cw6 allele expression and characteristics of Javanese ethnic psoriasis patients in Indonesia.Med. J. Indones.201928437037410.13181/mji.v28i4.3283
     [Google Scholar]
  7. AntalD. AlimohammadiS. BaiP. SzöllősiA.G. SzántóM. Antigen-presenting cells in psoriasis.Life202212223410.3390/life12020234 35207521
     [Google Scholar]
  8. WaljeeA.K. HigginsP.D.R. JensenC.B. Anti-tumour necrosis factor-α therapy and recurrent or new primary cancers in patients with inflammatory bowel disease, rheumatoid arthritis, or psoriasis and previous cancer in Denmark: A nationwide, population-based cohort study.Lancet Gastroenterol. Hepatol.20205327628410.1016/S2468‑1253(19)30362‑0 31836320
     [Google Scholar]
  9. SezinT. KempenL. MeyneL.M. MousaviS. ZillikensD. SadikC.D. GPR15 is not critically involved in the regulation of murine psoriasiform dermatitis.J. Dermatol. Sci.201994119620410.1016/j.jdermsci.2019.01.008 30935778
     [Google Scholar]
  10. GaoX. ZhangY. SaumK.U. SchöttkerB. BreitlingL.P. BrennerH. Tobacco smoking and smoking-related DNA methylation are associated with the development of frailty among older adults.Epigenetics201712214915610.1080/15592294.2016.1271855 28001461
     [Google Scholar]
  11. Martínez-RezaI. DíazL. García-BecerraR. Preclinical and clinical aspects of TNF-α and its receptors TNFR1 and TNFR2 in breast cancer.J. Biomed. Sci.20172419010.1186/s12929‑017‑0398‑9 29202842
     [Google Scholar]
  12. KingoK. MössnerR. KõksS. Association analysis of IL19, IL20 and IL24 genes in palmoplantar pustulosis.Br. J. Dermatol.2007156464665210.1111/j.1365‑2133.2006.07731.x 17263806
     [Google Scholar]
  13. MidtbøH. KringelandE. GerdtsE. Biomarkers of inflammation and left ventricular remodelling in psoriasis patients treated with infliximab.Int. J. Immunopathol. Pharmacol.20223610.1177/03946320221111131 35968808
     [Google Scholar]
  14. BarkerJ. GirolomoniG. EgebergA. GoncalvesJ. PieperB. KangT. Anti-TNF biosimilars in psoriasis: From scientific evidence to real-world experience.J. Dermatolog. Treat.201916234 31094242
     [Google Scholar]
  15. ArmstrongA.W. ReadC. Pathophysiology, clinical presentation, and treatment of psoriasis: A review.JAMA2020323191945196010.1001/jama.2020.4006 32427307
     [Google Scholar]
  16. FergusonJ.E. SegerE.W. WhiteJ. McMichaelA. Racial/ethnic differences in treatment efficacy and safety for moderate-to-severe plaque psoriasis: A systematic review.Arch. Dermatol. Res.20223151415010.1007/s00403‑022‑02324‑4 35050396
     [Google Scholar]
  17. KaramanakosA. VergouT. PanopoulosS. TektonidouM.G. StratigosA.J. SfikakisP.P. Psoriasis as an adverse reaction to biologic agents beyond anti-TNF-α therapy.Eur. J. Dermatol.202131330731710.1684/ejd.2021.4056 34309516
     [Google Scholar]
  18. MelsheimerR. GeldhofA. ApaolazaI. SchaibleT. Remicade® (infliximab): 20 years of contributions to science and medicine.Biologics201913139178 31440029
     [Google Scholar]
  19. ZhouY. FanR. BotchwayB.O.A. ZhangY. LiuX. Infliximab can improve traumatic brain injury by suppressing the tumor necrosis factor alpha pathway.Mol. Neurobiol.20215862803281110.1007/s12035‑021‑02293‑1 33501626
     [Google Scholar]
  20. CourbetteO. AupiaisC. VialaJ. Infliximab paradoxical psoriasis in a cohort of children with inflammatory bowel disease.J. Pediatr. Gastroenterol. Nutr.201969218919310.1097/MPG.0000000000002349 30921262
     [Google Scholar]
  21. HongJ. LeeY. LeeC. Physicochemical and biological characterization of SB2, a biosimilar of Remicade® (infliximab).MAbs20179236538310.1080/19420862.2016.1264550 28005456
     [Google Scholar]
  22. SharmaK. KumarS. Current strategies for the management of psoriasis with potential pharmacological pathways using herbals and immuno-biologicals.Curr. Mol. Pharmacol.202417e15092322116310.2174/1874467217666230915125613 37724681
     [Google Scholar]
  23. Ovejero-BenitoM.C. Muñoz-AceitunoE. SabadorD. Genome‐wide association analysis of psoriasis patients treated with anti‐TNF drugs.Exp. Dermatol.202029121225123210.1111/exd.14215 33058233
     [Google Scholar]
  24. Kołt-KamińskaM. ŻychowskaM. ReichA. Infliximab in combination with low-dose acitretin in generalized pustular psoriasis: A report of two cases and review of the literature.Biologics202115317327 34393480
     [Google Scholar]
  25. Babuna KobanerG. Polat EkinciA. Infliximab for the treatment of recalcitrant generalized pustular psoriasis of pregnancy: Report of a challenging case.Dermatol. Ther. 2020334e1357110.1111/dth.13571 32406109
     [Google Scholar]
  26. EberhardtJ. Santos-MartinsD. TillackA.F. ForliS. AutoDock vina 1.2.0: New docking methods, expanded force field, and python bindings.J. Chem. Inf. Model.20216183891389810.1021/acs.jcim.1c00203 34278794
     [Google Scholar]
  27. SpencerR.K. ElhageK.G. JinJ.Q. Living with psoriasis vulgaris and multi-treatment failure: A patient and dermatologist perspective.Dermatol. Ther. 202313485786610.1007/s13555‑023‑00907‑1 36913122
     [Google Scholar]
  28. Montes-TorresA. AparicioG. RiveraR. Safety and effectiveness of conventional systemic therapy and biological drugs in patients with moderate to severe psoriasis and HIV infection: A retrospective multicenter study.J. Dermatolog. Treat.201930546146510.1080/09546634.2018.1535690 30307344
     [Google Scholar]
  29. MrowietzU. WarrenR.B. LeonardiC.L. Network meta‐analysis of biologic treatments for psoriasis using absolute Psoriasis Area and Severity Index values ≤1, 2, 3 or 5 derived from a statistical conversion method.J. Eur. Acad. Dermatol. Venereol.20213551161117510.1111/jdv.17130 33480102
     [Google Scholar]
  30. SyversenS.W. GollG.L. JørgensenK.K. Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (the NOR-DRUM study).Trials20202111310.1186/s13063‑019‑3734‑4 31907007
     [Google Scholar]
  31. PhanD.B. BewleyA.P. SmithC.H. Uptake of tumour necrosis factor-alpha inhibitor biosimilars for psoriasis: A drug utilization study from the british association of dermatologists biologic and immunomodulators register (BADBIR).Br. J. Dermatol.20231891627010.1093/bjd/ljad107 37016153
     [Google Scholar]
  32. SchadlerE.D. OrtelB. MehlisS.L. Biologics for the primary care physician: Review and treatment of psoriasis.Dis. Mon.2019653519010.1016/j.disamonth.2018.06.001 30037762
     [Google Scholar]
  33. StrandV. McInnesI. MeaseP. Matching-adjusted indirect comparison: Secukinumab versus infliximab in biologic-naive patients with psoriatic arthritis.J. Comp. Eff. Res.20198749751010.2217/cer‑2018‑0141 30806520
     [Google Scholar]
  34. GottliebA.B. EvansR. LiS. Infliximab induction therapy for patients with severe plaque-type psoriasis: A randomized, double-blind, placebo-controlled trial.J. Am. Acad. Dermatol.200451453454210.1016/j.jaad.2004.02.021 15389187
     [Google Scholar]
  35. ChaudhariU. RomanoP. MulcahyL.D. DooleyL.T. BakerD.G. GottliebA.B. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: A randomised trial.Lancet200135792711842184710.1016/S0140‑6736(00)04954‑0 11410193
     [Google Scholar]
  36. ReichK. NestleF.O. PappK. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: A phase III, multicentre, double-blind trial.Lancet200536694941367137410.1016/S0140‑6736(05)67566‑6 16226614
     [Google Scholar]
  37. MenterA. FeldmanS.R. WeinsteinG.D. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis.J. Am. Acad. Dermatol.200756131.e131.e1510.1016/j.jaad.2006.07.017 17097378
     [Google Scholar]
  38. de VriesA.C.Q. ThioH.B. de KortW.J.A. A prospective randomized controlled trial comparing infliximab and etanercept in patients with moderate-to-severe chronic plaque-type psoriasis: the Psoriasis Infliximab vs. Etanercept Comparison Evaluation (PIECE) study.Br. J. Dermatol.2017176362463310.1111/bjd.14867 27416891
     [Google Scholar]
  39. SubediS. GongY. ChenY. ShiY. Infliximab and biosimilar infliximab in psoriasis: Efficacy, loss of efficacy, and adverse events.Drug Des. Devel. Ther.2019132491250210.2147/DDDT.S200147 31413544
     [Google Scholar]
  40. SyversenS.W. GollG.L. JørgensenK.K. Effect of therapeutic drug monitoring vs standard therapy during infliximab induction on disease remission in patients with chronic immune-mediated inflammatory diseases.JAMA2021325171744175410.1001/jama.2021.4172 33944876
     [Google Scholar]
  41. MoritaA. NishikawaK. YamadaF. YamanakaK. NakajimaH. OhtsukiM. Safety, efficacy, and drug survival of the infliximab biosimilar CT‐P13 in post‐marketing surveillance of Japanese patients with psoriasis.J. Dermatol.2022491095796910.1111/1346‑8138.16508 35799412
     [Google Scholar]
  42. ShinD. KimY. KimY.S. KörnickeT. FuhrR. A randomized, phase I pharmacokinetic study comparing SB2 and infliximab reference product (Remicade®) in healthy subjects.BioDrugs2015296381388
     [Google Scholar]
  43. ChristianK.E. RussmanK.M. RajanD.P. BarrE.A. CrossR.K. Gender differences and other factors associated with weight gain following initiation of infliximab: A post hoc analysis of clinical trials.Inflamm. Bowel Dis.202026112513110.1093/ibd/izz133 31265730
     [Google Scholar]
  44. RoblinX. MarotteH. LeclercM. Combination of C-reactive protein, infliximab trough levels, and stable but not transient antibodies to infliximab are associated with loss of response to infliximab in inflammatory bowel disease.J. Crohn’s Colitis20159752553110.1093/ecco‑jcc/jjv061 25895875
     [Google Scholar]
  45. BitoT. NishikawaR. HatakeyamaM. Influence of neutralizing antibodies to adalimumab and infliximab on the treatment of psoriasis.Br. J. Dermatol.2014170492292910.1111/bjd.12791 24329764
     [Google Scholar]
  46. LichtensteinL. RonY. KivityS. Infliximab-related infusion reactions: Systematic review.J. Crohn’s Colitis20159980681510.1093/ecco‑jcc/jjv096 26092578
     [Google Scholar]
  47. GisondiP. VirgaC. PiasericoS. Switching from one infliximab biosimilar (CT‐P13) to another infliximab biosimilar (SB2) in patients with chronic plaque psoriasis.Br. J. Dermatol.2020183239739810.1111/bjd.19013 32133618
     [Google Scholar]
  48. LegrandP. DufaÿS. MignetN. HouzéP. GahoualR. Modeling study of long-term stability of the monoclonal antibody infliximab and biosimilars using liquid-chromatography–tandem mass spectrometry and size-exclusion chromatography–multi-angle light scattering.Anal. Bioanal. Chem.2023415117919210.1007/s00216‑022‑04396‑7 36449030
     [Google Scholar]
  49. KimJ. ChungJ. ParkS. JungS. KangD. Evaluation of the physicochemical and biological stability of reconstituted and diluted SB2 (infliximab).Eur. J. Hosp. Pharm. Sci. Pract.201825315716410.1136/ejhpharm‑2016‑001085 29732144
     [Google Scholar]
  50. ShieldsR.L. LaiJ. KeckR. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity.J. Biol. Chem.200227730267332674010.1074/jbc.M202069200 11986321
     [Google Scholar]
  51. RajuT.S. Terminal sugars of Fc glycans influence antibody effector functions of IgGs.Curr. Opin. Immunol.200820447147810.1016/j.coi.2008.06.007 18606225
     [Google Scholar]
  52. ScallonB.J. TamS.H. McCarthyS.G. CaiA.N. RajuT.S. Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality.Mol. Immunol.20074471524153410.1016/j.molimm.2006.09.005 17045339
     [Google Scholar]
  53. NupurN. JoshiS. GulliarmeD. RathoreA.S. Analytical similarity assessment of biosimilars: Global regulatory landscape, recent studies and major advancements in orthogonal platforms.Front. Bioeng. Biotechnol.20221083205910.3389/fbioe.2022.832059 35223794
     [Google Scholar]
  54. McKeageK. A review of CT-P13: An infliximab biosimilar.BioDrugs201428331332110.1007/s40259‑014‑0094‑1 24723086
     [Google Scholar]
  55. BlairH.A. DeeksE.D. Infliximab biosimilar (CT-P13; Infliximab-dyyb): A review in autoimmune inflammatory diseases.BioDrugs201630546948010.1007/s40259‑016‑0193‑2 27650650
     [Google Scholar]
  56. YooD.H. RacewiczA. BrzezickiJ. A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study.Arthritis Res. Ther.20161818210.1186/s13075‑016‑0981‑6 27038608
     [Google Scholar]
  57. McClellanJ.E. ConlonH.D. BoltM.W. The ‘totality-of-the-evidence’ approach in the development of PF-06438179/GP1111, an infliximab biosimilar, and in support of its use in all indications of the reference product.Therap. Adv. Gastroenterol.20191210.1177/1756284819852535 31223341
     [Google Scholar]
  58. YuanJ.J. GaoD. HuF. Isolation and characterization of charge variants of infliximab biosimilar HS626.J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.2021116212248510.1016/j.jchromb.2020.122485 33360415
     [Google Scholar]
  59. VincentF.B. MorandE.F. MurphyK. MackayF. MarietteX. MarcelliC. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: A real issue, a clinical perspective.Ann. Rheum. Dis.201372216517810.1136/annrheumdis‑2012‑202545 23178294
     [Google Scholar]
  60. Rubbert-RothA. SzabóM.Z. KedvesM. NagyG. AtzeniF. Sarzi-PuttiniP. Failure of anti-TNF treatment in patients with rheumatoid arthritis: The pros and cons of the early use of alternative biological agents.Autoimmun. Rev.2019181210239810.1016/j.autrev.2019.102398 31639514
     [Google Scholar]
  61. LecluseL.L.A. PiskinG. MekkesJ.R. BosJ.D. de RieM.A. Review and expert opinion on prevention and treatment of infliximab-related infusion reactions.Br. J. Dermatol.2008159352753610.1111/j.1365‑2133.2008.08728.x 18627374
     [Google Scholar]
  62. LandemaineA. PetitcollinA. BrochardC. Cumulative exposure to infliximab, but not trough concentrations, correlates with rate of infection.Clin. Gastroenterol. Hepatol.2021192288295.e410.1016/j.cgh.2020.03.018 32200087
     [Google Scholar]
  63. GomesC.M.F. TerreriM.T. Moraes-PintoM.I. PinheiroM.M. Performance of 4 methods for screening of latent tuberculosis infection in patients with chronic inflammatory arthritis under TNFα inhibitors: A 24-month prospective study.Adv. Rheumatol.20216117110.1186/s42358‑021‑00226‑z 34838126
     [Google Scholar]
  64. MojeskiJ.A. KalbR.E. Infliximab, golimumab, and certolizumab pegol. In: Advances in Psoriasis: A Multisystemic Guide. Springer 2021117399
     [Google Scholar]
  65. YocumD. Effective use of TNF antagonists. . Arthritis Res 20046Suppl 2)(Suppl. 2S243010.1186/ar997 15228618
     [Google Scholar]
  66. WongF. Al IbrahimB. WalshJ. QumosaniK. Infliximab‐induced autoimmune hepatitis requiring liver transplantation.Clin. Case Rep.20197112135213910.1002/ccr3.2456 31788265
     [Google Scholar]
  67. ThanN.T.T. YaşarÇ. PhamB.H. Bilateral retinal vasculitis associated with cold agglutinin disease treated with obinutuzumab and infliximab.Am. J. Ophthalmol. Case Rep.20222810175210.1016/j.ajoc.2022.101752 36425783
     [Google Scholar]
  68. TakamatsuH. YoroidakaT. Disappearance of bulky diffuse large B-cell lymphoma after methotrexate/infliximab withdrawal.Int. J. Hematol.202211511210.1007/s12185‑021‑03255‑y 34813047
     [Google Scholar]
  69. JarandJ. ZochodneD.W. MartinL.O. VollC. Neurological complications of infliximab.J. Rheumatol.200633510181020 16511935
     [Google Scholar]
  70. MössnerR. FrambachY. Wilsmann-TheisD. Palmoplantar pustular psoriasis is associated with missense variants in CARD14, but not with loss-of-function mutations in IL36RN in European patients.J. Invest. Dermatol.2015135102538254110.1038/jid.2015.186 25989471
     [Google Scholar]
  71. DenadaiR. TeixeiraF.V. Saad-HossneR. The onset of psoriasis during the treatment of inflammatory bowel diseases with infliximab: Should biological therapy be suspended?Arq. Gastroenterol.201249217217610.1590/S0004‑28032012000200014 22767007
     [Google Scholar]
  72. GeldhofA. SlaterJ. ClarkM. ChandranU. CoppolaD. Exposure to infliximab during pregnancy: post-marketing experience.Drug Saf.202043214716110.1007/s40264‑019‑00881‑8 31677004
     [Google Scholar]
  73. BakkerA.L.M. MathijssenH. AzzahhafiJ. Effectiveness and safety of infliximab in cardiac Sarcoidosis.Int. J. Cardiol.202133017918510.1016/j.ijcard.2021.02.022 33582196
     [Google Scholar]
  74. MassonW. LoboM. MolineroG. Psoriasis and cardiovascular risk: A comprehensive review.Adv. Ther.20203752017203310.1007/s12325‑020‑01346‑6 32314303
     [Google Scholar]
  75. JiE. LeeS. Antibody-based therapeutics for atherosclerosis and cardiovascular diseases.Int. J. Mol. Sci.20212211577010.3390/ijms22115770 34071276
     [Google Scholar]
  76. VighN. LevyD. Lactic acidemia due to an infliximab infusion reaction.Am. J. Emerg. Med.2020384850.e1850.e310.1016/j.ajem.2019.11.005 31831342
     [Google Scholar]
  77. VipaweeS. Translating the 2019 AAD-NPF guidelines of care for psoriasis with attention to comorbidities.Cutis20211082S711
     [Google Scholar]
  78. YamazakiF. Psoriasis: Comorbidities.J. Dermatol.202148673274010.1111/1346‑8138.15840 33763899
     [Google Scholar]
  79. KaushikS.B. LebwohlM.G. Psoriasis: Which therapy for which patient.J. Am. Acad. Dermatol.2019801274010.1016/j.jaad.2018.06.057 30017705
     [Google Scholar]
  80. KormanN.J. Management of psoriasis as a systemic disease: What is the evidence?Br. J. Dermatol.2020182484084810.1111/bjd.18245 31225638
     [Google Scholar]
  81. KittlerN.W. CordoroK.M. Pediatric psoriasis comorbidities.Skin Therapy Lett.202025516 33196156
     [Google Scholar]
  82. KangB.Y. O’HaverJ. AndrewsI.D. Pediatric psoriasis comorbidities: Screening recommendations for the primary care provider.J. Pediatr. Health Care202135333735010.1016/j.pedhc.2020.12.006 34016447
     [Google Scholar]
  83. ConnorC.J. LiuV. FiedorowiczJ.G. Exploring the physiological link between psoriasis and mood disorders.Dermatol. Res. Pract.2015201511110.1155/2015/409637 26550011
     [Google Scholar]
  84. AmanatM. SalehiM. RezaeiN. Neurological and psychiatric disorders in psoriasis.Rev. Neurosci.201829780581310.1515/revneuro‑2017‑0108
     [Google Scholar]
  85. HedinC.R.H. SonkolyE. EberhardsonM. StåhleM. Inflammatory bowel disease and psoriasis: Modernizing the multidisciplinary approach.J. Intern. Med.2021290225727810.1111/joim.13282 33942408
     [Google Scholar]
  86. BassukasI. GaitanisG. KatsanosK. ChristodoulouD. TsianosE. VlachosC. Psoriasis and inflammatory bowel disease: Links and risks.Psoriasis 20166739210.2147/PTT.S85194 29387596
     [Google Scholar]
  87. MenterM.A. ArmstrongA.W. GordonK.B. WuJ.J. Common and not-so-common comorbidities of psoriasis.Semin. Cutan. Med. Surg.2018372S4851
     [Google Scholar]
  88. Schmitt‐EgenolfM. Physical activity and lifestyle improvement in the management of psoriasis.Br. J. Dermatol.2016175345245310.1111/bjd.14899
     [Google Scholar]
  89. AhdoutJ. KotlermanJ. ElashoffD. KimJ. ChiuM.W. Modifiable lifestyle factors associated with metabolic syndrome in patients with psoriasis.Clin. Exp. Dermatol.201237547748310.1111/j.1365‑2230.2012.04360.x
     [Google Scholar]
  90. IghaniA. PartridgeA.C.R. ShearN.H. Comparison of management guidelines for moderate-to-severe plaque psoriasis: A review of phototherapy, systemic therapies, and biologic agents.J. Cutan. Med. Surg.201923220422110.1177/1203475418814234 30463416
     [Google Scholar]
  91. RobinsonS. MoonT.M. EngT.K. Dermatology life quality index in patients with psoriasis treated with biologic versus non-biologic treatment in Malaysia: A retrospective cross-sectional study.Drugs Real World Outcomes202310229129810.1007/s40801‑023‑00359‑1 36840826
     [Google Scholar]
  92. ImafukuS. KanaiY. MurotaniK. Utility of the dermatology life quality index at initiation or switching of biologics in real-life Japanese patients with plaque psoriasis: Results from the prologue study.J. Dermatol. Sci.2021101318519310.1016/j.jdermsci.2021.01.002 33495058
     [Google Scholar]
  93. MenterA. GelfandJ.M. ConnorC. Joint american academy of dermatology–national psoriasis foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies.J. Am. Acad. Dermatol.20208261445148610.1016/j.jaad.2020.02.044 32119894
     [Google Scholar]
  94. ElstonD.M. American academy of dermatology and national psoriasis foundation guidelines of care for the management and treatment of psoriasis.J. Am. Acad. Dermatol.202184225725810.1016/j.jaad.2020.09.013 32926987
     [Google Scholar]
  95. Wine-LeeL. KellerS.C. WilckM.B. GluckmanS.J. Van VoorheesA.S. From the medical board of the national psoriasis foundation: Vaccination in adult patients on systemic therapy for psoriasis.J. Am. Acad. Dermatol.20136961003101310.1016/j.jaad.2013.06.046 24075223
     [Google Scholar]
  96. RobinsonA. Van VoorheesA.S. HsuS. Treatment of pustular psoriasis: From the medical board of the national psoriasis foundation.J. Am. Acad. Dermatol.201267227928810.1016/j.jaad.2011.01.032 22609220
     [Google Scholar]
/content/journals/cds/10.2174/0115748863320685240830092746
Loading
Long-term Safety Monitoring and Efficacy Status of Infliximab and its Biosimilars in Psoriasis Management
Curr Drug Saf 20, 271 (2025); https://doi.org/10.2174/0115748863320685240830092746
/content/journals/cds/10.2174/0115748863320685240830092746
/content/journals/cds/10.2174/0115748863320685240830092746
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): biosimilars; inflammation; Infliximab; infusion therapy; PASI; psoriasis; TNF

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test